biotech · PIK3CA Mutation · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation · RLAY
Relay Therapeutics
Relay Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker RLAY. Primary therapeutic focus areas include PIK3CA Mutation, PIK3CA Related Overgrowth Spectrum and Malformat
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 211
- Programs
- 6
- Drugs
- 7
- Patents
- 12
RLY-2608-102
Phase 3 · small molecule · PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer
RLY-2608-102 for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer is a Phase 3 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code RLY-2608-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Relay Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer
- Status
- active
- Trials
- 1